18F-DCFPyL and 18F-PSMA-JK7 for staging of primary prostate cancer: an interpatient comparison in 500 patients
No clinically relevant differences are found between PyL and JK7 for staging of primary prostate cancer. Both in terms of detection rates of primary tumor and metastases as well as in terms of PET true-negative and false-negative rates in the subcohort treated with surgery. This data indicates that the diagnostic value of JK7 is comparable to PyL.
Authors
- Sergiy V. Lazarenko
- Ton A. Roeleveld
- Remco J.J. Knol (ORCID: https://orcid.org/0000-0003-1089-2981)
- Maurits Wondergem (ORCID: https://orcid.org/0000-0001-8227-9145)
- Jeroen Doodeman
- Friso M. van der Zant
Institutions
- Endocrinology Northwest (US)
- Northwest Hospital (US)
- Northwest Cancer Clinic (US)
Publication Details
- Journal
- Nuclear Medicine Communications
- Published
- 2025-07-18
- DOI
- https://doi.org/10.1097/mnm.0000000000002027
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00